Tibotec initiates phase I hepatitis trial
The phase Ia clinical trial is designed to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The study will be conducted in Europe. Preclinical research conducted on
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.